Cohort study reveals increased risk of second primary malignant neoplasm after radioactive iodine treatment in distinct age groups, suggesting further surveillance is necessary.
Key Points
Increased risk of hematologic cancers in younger patients treated with radioactive iodine, highlighting age disparities in outcomes.
Among patients aged 15 to 44, myeloma risk rose notably with radioactive iodine (RR, 4.22; 95% CI, 1.68-10.62) after 14.7 years median follow-up.
This retrospective cohort study analyzed data from 72,412 patients with differentiated thyroid cancer across multiple cancer registries.
Findings support the need for tailored screening and monitoring strategies for second primary malignant neoplasms based on age.